Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...

We recently compiled a list of the 9 Best Dow Stocks to Buy According to Analysts. In this article, we are going to take a ...

Anyone crafting a bull case for the pharmaceutical giant Merck (NYSE: MRK) should include Keytruda as the ... The Motley Fool Stock Advisor analyst team just identified what they believe are ...

Merck (MRK) will be in focus as company beats revenue forecasts despite in line earnings amid strong Keytruda sales in Q3 ...

Merck stock fell early Monday after a rival pharmaceutical company said its cancer drug beat Merck’s Keytruda in a ...

Investors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming Keytruda. Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab ...

Merck (MRK) is set to announce Q3 earnings on October 31st. Analysts expect a profit of $1.57 per share on revenue of $16.51B ...

No stock has unlimited upside potential ... In a late-stage trial, the medicine performed better than Merck's Keytruda in treating non-small cell lung cancer (NSCLC) patients with PD-L1 protein ...

Merck & Co. on Wednesday said a late-stage study of a combination including its blockbuster cancer drug Keytruda missed its goal in certain patients with colorectal cancer. The Rahway, N.J ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...